1. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma
   Huijie Jia et al, 2018, International Journal of Oncology CrossRef
2. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1β signaling interruption
   Ahmed E. Khodir et al, 2020, Life Sciences CrossRef
3. Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis
   Xingping Su et al, 2023, European Journal of Medicinal Chemistry CrossRef
4. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation
   Mohamed M. Aboudounya et al, 2021, Mediators of Inflammation CrossRef
5. MicroRNAs as Potential Diagnostic, Prognostic, and Predictive Biomarkers for Acute Graft-versus-Host Disease
   Jamshid Motaei et al, 2019, Biology of Blood and Marrow Transplantation CrossRef
6. Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms
   Hanan S. Althagafy et al, 2023, European Journal of Pharmacology CrossRef
7. Renoprotective effect of nifuroxazide in diabetes-induced nephropathy: impact on NFκB, oxidative stress, and apoptosis
   Nehal M. Elsherbiny et al, 2018, Toxicology Mechanisms and Methods CrossRef
8. Screening a small hydrazide-hydrazone combinatorial library for targeting the STAT3 in monocyte-macrophages with insulated reporter transposons
   Valeri V. Mossine et al, 2023, Medicinal Chemistry Research CrossRef
9. Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNK/caspase-8/TRAIL activation in rats
   Ahmed E. Khodir et al, 2020, Life Sciences CrossRef
10. Regulation of IL-6/STAT-3/Wnt axis by nifuroxazide dampens colon ulcer in acetic acid-induced ulcerative colitis model: Novel mechanistic insight
    Fares E.M. Ali et al, 2021, Life Sciences CrossRef
11. T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
    Julia Campe et al, 2022, Frontiers in Immunology CrossRef
12. Toward a repositioning of the antibacterial drug nifuroxazide for cancer treatment
    Christian Bailly, 2019, Drug Discovery Today CrossRef
13. Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT
    Rebecca Harris et al, 2023, Frontiers in Immunology CrossRef
14. The interplay of the inhibitory effect of nifuroxazide on NF-κB/STAT3 signaling attenuates acetic acid-induced ulcerative colitis in rats
    Yousra M. El-Far et al, 2020, Environmental Toxicology and Pharmacology CrossRef
15. STAT signaling in the intestine
    Yael R. Nobel et al, 2021, Signal Transduction in Cancer and Immunity CrossRef
16. IDO2-siRNA Carried by Salmonella Combined with Nifuroxazide Attenuates Melanoma Growth
    Tiesuo Zhao et al, 2023, Current Molecular Pharmacology CrossRef
17. Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy
    Tiesuo Zhao et al, 2020, Journal of Cellular Biochemistry CrossRef